New CRISPR Gene Therapy Offers Hope for Permanent Cholesterol Reduction

A new CRISPR-based gene-editing therapy has shown remarkable early results in permanently lowering cholesterol by targeting the ANGPTL3 gene. Early clinical trials indicate that this innovative treatment could offer a long-term solution for patients suffering from severe or treatment-resistant high cholesterol, reducing their risk of heart disease.

New CRISPR Gene Therapy Offers Hope for Permanent Cholesterol Reduction

Targeting the ANGPTL3 Gene

The therapy disables the ANGPTL3 gene, which controls the amount of LDL (bad cholesterol) and triglycerides in the blood.
In a small clinical trial of 15 patients, those who received the highest dose experienced:

• 50% reduction in LDL cholesterol
• 55% drop in triglycerides

By lowering both harmful fats, this treatment can help prevent artery blockage and heart attacks.

Inspired by a Natural Mutation

Scientists developed this therapy based on a rare natural mutation found in about 1 in 250 people. Individuals with this mutation have a non-functional ANGPTL3 gene, resulting in naturally low cholesterol and triglyceride levels without side effects.
The CRISPR technique mimics this natural state by editing liver cells, which play a central role in cholesterol regulation, while keeping other tissues safe from alteration.

Safety and Clinical Findings

The initial human trial mainly tested the safety of this therapy. Most participants only experienced mild and temporary side effects, such as slight infusion reactions.
Although one participant with advanced heart disease died months later, investigators confirmed that the death was not related to the treatment.
Regulators have now approved Phase 2 and Phase 3 trials to evaluate long-term safety and effectiveness, with participants to be monitored for up to 15 years.

Future of Cholesterol Management

If successful, this one-time gene-editing treatment could revolutionize cholesterol management and heart disease prevention.
It may replace the need for lifelong medications, especially for patients who cannot tolerate statins or other cholesterol-lowering drugs.
However, experts emphasize that more large-scale trials are necessary before it becomes a routine medical option.

Exam-Oriented Notes

• The therapy targets the ANGPTL3 gene, which regulates LDL and triglycerides.
• It uses CRISPR-Cas9 technology to precisely edit liver cells.
• People with inactive ANGPTL3 genes naturally maintain low cholesterol levels.
• The Phase 1 trial showed up to 50% LDL reduction and 55% triglyceride reduction.
• Future trials (Phase 2 and 3) will focus on long-term safety and results.

Also Read

Question & Answer

Q1. Which gene is targeted by the new CRISPR-based therapy for cholesterol reduction?
(a) APOE
(b) ANGPTL3
(c) LDLR
(d) PCSK9
Answer: ANGPTL3

Q2. What percentage of LDL cholesterol reduction was observed in patients receiving the highest dose?
(a) 25%
(b) 40%
(c) 50%
(d) 65%
Answer: 50%

Q3. What technology does the new cholesterol therapy use?
(a) RNA sequencing
(b) CRISPR-Cas9 gene editing
(c) Nanoparticle targeting
(d) Stem cell therapy
Answer: CRISPR-Cas9 gene editing

Q4. In which part of the body does the therapy edit cells to regulate cholesterol?
(a) Heart cells
(b) Muscle cells
(c) Liver cells
(d) Blood cells
Answer: Liver cells

Q5. People with a natural ANGPTL3 mutation have which characteristic?
(a) High triglycerides
(b) Naturally low cholesterol
(c) Increased heart disease risk
(d) Poor liver function
Answer: Naturally low cholesterol

🔗 Other Useful Links:
📌 Latest Government Job Vacancies
📌 Latest Exam Results
📌 Free Mock Tests